Company intelligence / Profile preview

Sabaflk

Sioux Falls, South Dakota, USAbancsabadell.com ↗

Ownership: Private
Development stage: Other

Overview

SAB BIO's lead candidate, SAB‑142, has shown safety and immunogenicity with no serum sickness or neutralizing anti-drug antibodies across seven clinical trials involving over 700 individuals; it aims to delay onset/progression of type 1 diabetes by modulating immune response.

Therapeutic areas: ImmunologyEndocrinology
Modalities: Antibody
Industry: Biotech

Partnerships

US government agencies

Beyond the preview

Go deeper on Sabaflk.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sabaflk.

Explore the full profile